KRAS MUTATION IN EGFR WILD TYPE INDONESIAN LUNG CANCER PATIENT

被引：0
|
作者：
Masykura, Najmiatul [1 ]
Kharunisa, Bela Haifa [1 ]
Zaini, Jamal [2 ,3 ]
Andarini, Sita Laksmi [2 ,3 ]
Hudoyo, Achmad [2 ,3 ]
Syahruddin, Elisna [2 ]
Hidajat, Heriawaty [2 ]
Widjajahakim, Grace [4 ]
Utomo, Ahmad [1 ,4 ]
机构：
[1] Kalbe Farma Tbk, Stem Cell & Canc Inst, Kota Jakarta Timur, Indonesia
[2] Persahabatan Hosp, Jakarta, Indonesia
[3] Univ Indonesia, Fac Med, Jakarta, Indonesia
[4] Kalbe Genom Lab, Jakarta Timur, Indonesia
来源：
RESPIROLOGY | 2017年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
AO159
引用
收藏
页码：73 / 73
页数：1
相关论文
共 50 条
  • [1] EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
    Chalela, Roberto
    Gonzalez-Garcia, Jose Gregorio
    Khilzi, Karys
    Curull, Victor
    Sanchez-Font, Albert
    Longaron, Raquel
    Rodrigo-Calvo, Maria Teresa
    Martin-Ontiyuelo, Clara
    Gea, Joaquim
    Bellosillo, Beatriz
    PATHOLOGY & ONCOLOGY RESEARCH, 2021, 27
  • [2] Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS
    Furugaki, Koh
    Iwai, Toshiki
    Shirane, Masatoshi
    Kondoh, Kumiko
    Moriya, Yoichiro
    Mori, Kazushige
    ONCOLOGY REPORTS, 2010, 24 (05) : 1141 - 1146
  • [3] Detection of Kras Mutation from Urine of Indonesian Lung Cancer Patients
    Ridwanuloh, A.
    Fadiyah, F.
    Patria, F.
    Yasril, R.
    Hudoyo, A.
    Zaini, J.
    Andarini, S.
    Masykura, N.
    Utomo, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S662 - S662
  • [4] Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer
    A Choughule
    R Sharma
    V Trivedi
    A Thavamani
    V Noronha
    A Joshi
    S Desai
    P Chandrani
    P Sundaram
    S Utture
    N Jambhekar
    S Gupta
    J Aich
    K Prabhash
    A Dutt
    British Journal of Cancer, 2014, 111 : 2203 - 2204
  • [5] Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer
    Choughule, A.
    Sharma, R.
    Trivedi, V.
    Thavamani, A.
    Noronha, V.
    Joshi, A.
    Desai, S.
    Chandrani, P.
    Sundaram, P.
    Utture, S.
    Jambhekar, N.
    Gupta, S.
    Aich, J.
    Prabhash, K.
    Dutt, A.
    BRITISH JOURNAL OF CANCER, 2014, 111 (11) : 2203 - 2204
  • [6] Significance of EGFR and KRAS gene mutation in small cell lung cancer.
    Kurokawa, Koji
    Matsui, Tomoharu
    Ikeda, Hideko
    Nishikawa, Shingo
    Sone, Takashi
    Kasahara, Kazuo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] A POOLED ANALYSIS TO EVALUATE THE PROGNOSIS AND PREDICTIVE VALUE OF EGFR MUTATION ON SURVIVAL IN PATIENTS WITH KRAS WILD-TYPE LUNG ADENOCARCINOMA
    Soria, Jean-Charles
    Brambilla, Elisabeth
    Le Teuff, Gwenael
    Tsao, Ming S.
    Janne, Pasi A.
    Hainaut, Pierre
    Taron, Miquel
    Kratzke, Robert A.
    Shepherd, Frances A.
    Pignon, Jean-Pierre
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S617 - S617
  • [8] Plasma KRAS mutation in Indonesian lung cancer patients with smoking history, treated with chemotherapy
    Masykura, N.
    Andarini, S.
    Spp, E. K. Syahruddin
    Zaini, J.
    Hudoyo, A.
    Santoso, Y.
    Mirandari, A.
    Utomo, A. R.
    ANNALS OF ONCOLOGY, 2018, 29 : 145 - 145
  • [9] Relation of EGFR and KRAS mutation status with phosphorylation of EGFR in lung adenocarcinomas
    Brcic, L.
    Popper, H.
    VIRCHOWS ARCHIV, 2016, 469 : S327 - S327
  • [10] Optimisation of EGFR TKI efficiency wild-type EGFR lung cancer
    Raimbourg, Judith
    Cabart, Mathilde
    Joalland, Marie-Pierre
    Decaudin, Didier
    Deplater, Ludmilla
    Lanoe, Didier
    Douillard, Jean-Yves
    Bennouna, Jaafar
    Vallette, Francois
    Lalier, Lisenn
    CANCER RESEARCH, 2015, 75
12345